Core Points - The major shareholder, Southern Tongzheng, will have 11,761.7 million restricted shares judicially sold due to a contractual dispute, accounting for 92.51% of its holdings and 9.07% of the company's total share capital [1] - The sale will occur from November 23, 2025, to January 22, 2026, and will not lead to a change in the company's actual control or affect its production and operations [1] - Previous auctions on November 1-2 resulted in the sale of 6.2089 million shares for 33.6507 million yuan, with a buyer named Zhang Yu; an additional 7 million shares are set for auction on November 16-17 [1] - As of the announcement date, Southern Tongzheng holds 127 million shares, representing 9.80% of the total share capital, all of which are pledged and frozen [1]

证券代码：000566 证券简称：海南海药 公告编号：2025-068 海南海药股份有限公司 二、股东股份累计被拍卖情况 武汉中院于 2025 年 11 月 1 日 10 时至 2025 年 11 月 2 日 10 时止（延时除外）， 对公司持股 5%以上股东南方同正所持海南海药已质押的 123,825,900 股股票， 1 进行第二次公开司法拍卖, 本次拍卖成交股份共计 6,208,900 股，成交价格共计 33,650,726.39 元，竞买人为张宇，成交股份占公司股份总数的 0.48%。上述拍 卖标的物最终成交以湖北省武汉市中级人民法院出具拍卖成交裁定为准。 同时武汉中院于 2025 年 11 月 16 日 10 时至 2025 年 11 月 17 日 10 时止（延时除外）将南方同正所持海南海药 7,000,000 股进行公开司法拍卖， 占其所持股份比例 5.51%，占公司总股本比例 0.54%。具体内容详见公司分别于 2025 年 10 月 18 日及 2025 年 11 月 5 日在巨潮资讯网（www.cninfo.com.cn）披 露的《关于持股 5%以上股东部分股份被司法拍卖的进展公告》（公告 ...

Core Insights - Hainan Haiyao's stock price increased by 2.13% on November 7, reaching 6.24 CNY per share, with a total market capitalization of 8.096 billion CNY [1] - The company has seen a year-to-date stock price increase of 30.27%, with a recent 20-day increase of 14.29% [1] - For the period from January to September 2025, Hainan Haiyao reported a revenue of 640 million CNY, a year-on-year decrease of 20.51%, while the net profit attributable to shareholders was -242 million CNY, reflecting a year-on-year increase of 17.91% [2] Company Overview - Hainan Haiyao, established on December 30, 1992, and listed on May 25, 1994, is located in Haikou, Hainan Province [1] - The company's main business includes traditional Chinese and Western medicine, fine chemical products, chemical raw materials, health products, and related import-export trade [1] - The revenue composition includes: Other varieties 29.93%, Gastrointestinal health 25.07%, Medical services 18.60%, Raw materials and intermediates 13.27%, Cephalosporin series 10.19%, Others (supplement) 2.95% [1] Shareholder and Market Data - As of October 31, 2025, Hainan Haiyao had 75,600 shareholders, a decrease of 2.47% from the previous period, with an average of 15,420 circulating shares per shareholder, an increase of 2.53% [2] - The company has cumulatively distributed 466 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]

Core Insights - Hainan Haiyao reported that as of October 31, 2025, the number of shareholders is 75,607 [2] Company Summary - The company is actively engaging with investors through interactive platforms [2] - The increase in shareholder count may indicate growing investor interest and confidence in the company [2]

Core Viewpoint - Hainan Haiyao (000566) has seen a net financing inflow of 1.207 million yuan on November 4, 2025, with a total financing balance of 304 million yuan, indicating a positive trend in investor interest over the past three trading days [1][2][3] Financing Activity Summary - On November 4, 2025, the net financing inflow was 1.207 million yuan, with a financing balance of 304 million yuan, representing 4.21% of the circulating market value [2] - The financing balance increased by 0.4% from the previous day, reflecting a consistent upward trend in financing activities [3] - Over the last three trading days, the cumulative net financing inflow reached 25.7787 million yuan, indicating strong investor confidence [1] Historical Financing Data - The financing balance on November 3, 2025, was 303 million yuan, with a net inflow of 21.2888 million yuan, marking a significant increase of 7.55% [3] - On October 31, 2025, the financing balance was 282 million yuan, with a net inflow of 3.2829 million yuan, showing a smaller increase of 1.18% [3] - The financing balance has shown a steady increase from 278 million yuan on October 29, 2025, to 304 million yuan on November 4, 2025 [3]

Core Points - Hainan Haiyao announced the results of a judicial auction involving shares held by its second-largest shareholder, Shenzhen Nanfang Tongzheng Investment Co., Ltd, with 124 million shares being auctioned, of which only 6.21 million shares were sold, while 117 million shares went unsold [1][2] - The auctioned shares represented 92.86% of the total shares held by Nanfang Tongzheng and 9.54% of Hainan Haiyao's total share capital [1] - The successful bidder acquired shares at an average price of 5.42 CNY per share, approximately 13% lower than the latest closing price of 6.21 CNY [1] Shareholding Changes - Prior to the auction, Nanfang Tongzheng held 133 million shares, accounting for 10.28% of the total share capital, which decreased to 127 million shares or 9.80% post-auction, maintaining its position as the second-largest shareholder [2] - The company clarified that Nanfang Tongzheng is not a controlling shareholder, and the auction will not affect Hainan Haiyao's control or daily operations [2] Financial Performance - Hainan Haiyao is facing significant financial losses, with projected net profits of -106 million CNY for 2023 and -1.525 billion CNY for 2024 [2] - The Q3 2025 report indicated a revenue of 640 million CNY, a year-on-year decline of 20.5%, with net losses improving slightly from -295 million CNY to -242 million CNY compared to the same period last year [2]

Core Viewpoint - Hainan Haiyao (000566.SZ) announced the judicial auction of 124 million shares pledged by its major shareholder, Southern Tongzheng, which represents 92.86% of their total holdings and 9.54% of the company's total share capital [1] Summary by Relevant Sections - **Auction Details** - The auction resulted in the sale of 6.2089 million shares for a total price of 33.6507 million yuan, while 118 million shares remained unsold [1] - The buyer of the sold shares is Zhang Yu, and the shares sold account for 0.48% of the company's total shares [1] - **Impact on Company Control** - Southern Tongzheng is not the controlling shareholder of the company, and the auction of their shares will not lead to a change in control of the company [1] - The auction will not affect the normal production and operational activities of the company [1] - **Restrictions on Share Transfer** - The buyer of the auctioned shares is prohibited from reducing their holdings within six months after the acquisition [1]

证券代码：000566 证券简称：海南海药 公告编号：2025-067 海南海药股份有限公司 关于持股 5%以上股东部分股份被司法拍卖的结果公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 1 股份被司法拍卖的提示性公告》（公告编号：2025-059）和《关于持股 5%以上 股东部分股份被司法拍卖的进展公告》（公告编号：2025-060，2025-061） 二、本次拍卖的竞买结果情况 根据 2025 年 11 月 2 日京东网司法拍卖网络平台公示的《成交确认书》，本 次拍卖成交总价格为 33,650,726.39 元，竞买人为张宇，本次拍卖成交共计 6,208,900 股，占公司股份总数的 0.48%。具体成交情况如下： 特别提示 1、本次司法拍卖标的为公司持股 5%以上股东深圳市南方同正投资有限公司 （以下简称"南方同正"）所持海南海药股份有限公司（以下简称"公司"或"海 南海药"）已质押的 123,825,900 股股票，占其所持公司全部股份的 92.86%， 占公司总股本的 9.54%。 2、根据京东司法拍卖平台页面显示的拍卖结果，截至本公告披露日， ...

Policy Developments - The National Health Commission and five other departments launched a one-year special campaign against illegal ambulances, targeting both registered "ambulance" vehicles and unregistered "black ambulances" [2] - The campaign includes comprehensive inspections, management principles, and encourages social participation in medical transport services [2][3] Drug and Medical Device Approvals - Aied Bio received a medical device registration certificate for its gene mutation detection kit, which is now approved in China, Japan, and Europe, aiding non-small cell lung cancer patients [4] - Hainan Haiyao's subsidiary obtained a drug registration certificate for Fumaric Acid Vonoprazan Tablets, the first P-CAB for reflux esophagitis in China [5] Capital Market Activities - China National Pharmaceutical Modern signed a drug listing license transfer contract for Lactulose Oral Solution, with a total transfer fee of 5.86 million yuan, projected to generate 2.069 billion yuan in sales in 2024 [6] - Jiangsu Hengrui Medicine and Neurocrine Biosciences entered a collaboration for developing NLRP3 inhibitors, with a potential total value of $881.5 million [7][8] Industry Events - The 2025 medical insurance negotiation concluded, with results expected to be announced in early December [9] - The only approved stem cell drug in China, Aimi Maito Sai Injection, is included in the "Beijing Universal Health Insurance" with a maximum reimbursement of 65% [10] Regulatory Issues - The executive director of CSPC Pharmaceutical Group was fined 5 million yuan for insider trading related to a merger announcement [11]

Group 1 - China Mobile's controlling shareholder, China Mobile Group, plans to transfer 41.98 million shares (0.19% of total shares) to China National Petroleum Corporation [1] - Strong瑞 Technology intends to invest 70 million yuan to acquire 35% equity in aluminum cooling technology company, which supplies components for NVIDIA AI servers [2] - Pingtan Development's stock price has increased over 100% in the last eight trading days, indicating significant abnormal trading behavior [3] Group 2 - Hezhong China warns of irrational speculation risk as its stock price has surged 61.23% over five consecutive trading days, significantly deviating from its fundamentals [4] - TCL Technology's participation in the restructuring plan of Suning Group has not been approved by creditors, leading to uncertainties in the restructuring process [5] - Huitian New Materials has signed a strategic cooperation agreement with Taiblue New Energy to collaborate in solid-state batteries and key materials [6] Group 3 - Han Jian He Shan has signed a procurement contract worth 207 million yuan with China Nuclear Industry Huaxing Construction, accounting for 26.29% of its audited revenue for 2024 [7] - Actual controller of Baihehua, Chen Lirong, mistakenly reduced his holdings by 160,000 shares but has since repurchased the same amount [8][9] - Yaxing Chemical is planning to acquire control of Tianyi Chemical through a combination of share issuance and cash payment, leading to a stock suspension [10] Group 4 - Shenghui Integration's shareholder, Suzhou Shengzhan, has terminated its plan to reduce holdings of up to 620,000 shares, having already reduced 565,500 shares [11] - North Bay Port reported a 22.73% year-on-year increase in cargo throughput in October [12] - Jiangling Motors experienced an 8.06% year-on-year increase in automobile sales in October [12]